Waystar Holding Corp. (WAY) Company Overview

Waystar Holding Corp. is a Nasdaq-listed healthcare software company whose cloud platform helps providers collect payment from insurers and patients. The company sits inside the revenue cycle: the administrative chain that begins before a patient receives care and continues through eligibility checks, prior authorization, coding, claims submission, denial management, remittance, patient billing, and reconciliation. Its stated mission is to simplify healthcare payments so providers can spend more time on care and improve financial performance, a positioning described in Waystar’s official company overview.

Where does the platform sit in healthcare?

Waystar serves practices, clinics, laboratories, ambulatory surgery centers, hospitals, and health systems across the United States and its territories. Roughly one-third of revenue comes from hospitals and health systems and two-thirds from ambulatory and alternate sites. Ambulatory sales cycles are generally shorter; health-system contracts are larger but require deeper integration and security review.

Waystar combines recurring subscription fees with usage-based fees. Together they produced 99% of revenue in the company’s 2025 Form 10-K. Subscription revenue generally reflects monthly provider-count charges and contractual minimums. Volume-based revenue rises with claims, transactions, payment dollars, or provider activity above minimum levels. Implementation services and hardware are economically secondary.

Which solution economics matter most?

Visibility is central: 98% of FY2025 revenue came from clients already under contract when the year began. Growth therefore depends mainly on retention, cross-selling, provider expansion, pricing, and transaction volume.

For the quarter ended March 31, 2026, Waystar reported $313.9 million of revenue, up 22.4% year over year. The Q1 2026 earnings release showed both strong growth and expanding profitability, while the accompanying Form 10-Q explains the expense and cash-flow details.

Is growth accelerating or acquisition-driven?

The strongest signal is 38% subscription growth. Depreciation and amortization rose 24.2% to $41.5 million because of Iodine intangibles, interest expense reached $20.6 million, and R&D rose 65.8% to $18.4 million. Waystar is reinvesting rather than harvesting all incremental profit.

Waystar’s recurring revenue coexists with transaction-processing costs and acquisition amortization, creating a meaningful gap between adjusted EBITDA and GAAP income. For FY2025 it reported $1.099 billion of revenue, $249.3 million of operating income, $112.1 million of net income, $309.7 million of operating cash flow, and $365 million of unlevered free cash flow in its FY2025 results.

What is the key financial trade-off?

Recurring cash flow and $500 million of undrawn revolver capacity at December 31, 2025 support liquidity. Most principal was due in 2029, making interest, refinancing, and debt repayment genuine DCF drivers.

Waystar is a consolidation and platform-building story: it assembled broad revenue-cycle capabilities, integrated large data flows, used an IPO to reduce leverage, and then made another major acquisition.

1. 2017
   Waystar was formed from longtime healthcare-payment software foundations, including Navicure and ZirMed. The combination created a broader platform and installed base rather than a narrow point solution.
2. 2019
   A sponsor-backed capital structure and first-lien financing supported expansion. This accelerated scale but left leverage as a lasting analytical issue.
3. 2021
   The Patientco acquisition expanded patient financial engagement and payments; Waystar added $317M of incremental first- and second-lien financing in connection with the transaction.
4. 2023
   HealthPay24 was acquired for $31.4M, adding patient engagement and payment capabilities while reinforcing the end-to-end model.
5. 2024
   Waystar sold 45.0M shares at $21.50 in its IPO and used approximately $909.1M of net proceeds to repay first-lien debt, according to the IPO prospectus.
6. 2024
   After a major competitor’s cybersecurity incident, more than 30,000 providers began adopting Waystar solutions; many implementations were completed in as little as 48 hours. The event demonstrated operational resilience and accelerated switching.
7. 2025
   The $1.26B Iodine acquisition moved Waystar upstream into clinical documentation and utilization intelligence, strengthening the autonomous-revenue-cycle strategy.

What did the IPO change?

The IPO broadened access to equity capital and reduced first-lien principal by $909.1 million, lowering FY2025 interest expense. Iodine then confirmed that acquisitions remain central. Future cash flow must balance deleveraging, product investment, and possible deals.

Waystar’s moat combines data scale, workflow breadth, switching costs, payer connectivity, implementation capability, and reimbursement expertise. In 2025 it processed 7.5 billion-plus transactions representing over $2.4 trillion of gross claims and touching about 60% of U.S. patients. That data improves automation while installed integrations make replacement disruptive.

Why do claims data and AI matter?

Approximately 50% of Waystar solutions leveraged AI in FY2025. The company’s AltitudeAI strategy uses de-identified claims and operational data to predict denials, automate work, generate content, and support agentic workflows. The strategic resource is not AI in isolation; it is AI trained on proprietary revenue-cycle data and embedded in mission-critical processes. The company’s official platform description emphasizes the combination of agentic, generative, and predictive capabilities.

How durable are the switching costs?

Replacing claims, remittance, eligibility, payment, and denial systems requires migration, payer connections, retraining, EHR integration, and compliance review. Waystar reported an 85% average win rate in decided competitive opportunities during 2023-2025, evidence of product strength but not a market-share measure.

The market is fragmented among revenue-cycle platforms, workflow-specific point solutions, and EHR or practice-management vendors extending into payments. Large platforms can bundle; startups can innovate narrowly. Waystar’s advantage is breadth, but breadth is harder to integrate consistently.

What does market position look like?

Management estimates a $20 billion 2025 addressable market, rising about 5% annually to nearly $25 billion by 2030. TAM is not verified market share; stronger evidence is 30,000-plus clients, more than one million providers, 1,433 large clients, and 16 of 20 institutions on the U.S. News Best Hospitals list.

Waystar has one-vote-per-share common stock, but private-equity sponsors and large institutions still influence governance. The 2026 proxy statement, using ownership information as of April 10, 2026, reported 191.8 million shares outstanding for the beneficial-ownership table.

Does sponsor influence still matter?

EQT, CPPIB, and Bain retain board-nomination rights at ownership thresholds, and the board remains classified until their collective voting power falls below a defined level. All directors except CEO Matthew Hawkins were deemed independent, and standing committees contain only independent directors. Sponsor expertise can aid strategy, while registration rights and secondary sales create supply overhang.

Retention, client expansion, revenue mix, and cash conversion explain Waystar better than client count alone. NRR and the large-client cohort show whether cross-selling offsets churn.

Where can growth come from?

Growth can come from cross-selling modules, winning systems that want fewer vendors, extending upstream through Iodine, expanding digital patient payments, and automating labor-intensive reimbursement work. Each route increases revenue per client without requiring a new installed base.

What does management expect for 2026?

As of April 29, 2026, guidance called for $1.274-$1.294 billion of revenue, $530-$540 million of adjusted EBITDA, $317-$335 million of non-GAAP net income, and $1.59-$1.68 of diluted non-GAAP EPS. Midpoints imply about 17% revenue growth and a 41.6% adjusted EBITDA margin.

Key risks are security, regulation, competition, acquisition execution, and leverage. Because Waystar handles sensitive healthcare and payment data, disruption can affect client cash flow and patients. It is a HIPAA covered entity for clearinghouse activities and a business associate for other services.

Which risk is most material?

The highest-impact operational risk is a cyber or availability failure. The immediate financial risk is post-Iodine leverage: interest expense increased and goodwill reached about $4.0 billion. Weak acquired growth could pressure cash conversion and trigger impairment concerns.

A Waystar DCF should separate operating economics from acquisition accounting and capital structure. Recurring contracts, NRR, cross-selling, and volume support growth, while software investment, taxes, integration, and interest absorb cash. Adjusted EBITDA is useful, but GAAP operating income and cash flow remain essential checks.

Which assumptions deserve the most sensitivity testing?

Sensitivity tests should cover organic growth, NRR normalization, EBITDA-to-cash conversion, patient-payment mix, Iodine synergies, and debt repayment. A downside case can pair slower cross-selling with elevated interest; an upside case can assume clinical intelligence expands subscription revenue efficiently.

Waystar is a scaled healthcare-payment platform with recurring revenue, expansion inside existing accounts, and a large proprietary data network. It solves the costly problem of converting clinical activity into accurate payment across fragmented payer and patient workflows. Breadth, integrations, data, and implementation capability support switching costs and cross-selling.

Iodine expands strategic reach but increased debt, amortization, goodwill, and integration risk. Q1 2026 delivered 22.4% revenue growth, a 25.6% GAAP operating margin, 43% adjusted EBITDA margin, and $84.9 million of operating cash flow; NRR was 110.5% with 1,433 large clients.